Kidcal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kidcal

Property Description
Active ingredient Calcium Carbonate, Dihydrotachysterol (DHT)
Form Tablets, Oral Solution (Liquid)
Pharmacological class Calcium regulator, Vitamin D analogue
Common use Supporting calcium balance and bone density
Origin Synthetic analogue (DHT) combined with an Inorganic salt

Kidcal is defined as a specialized combination medication with a dual mechanism, supplying a crucial mineral along with a specific regulatory agent to support the body’s calcium economy. This formulation positions it as an agent for both mineral supplementation and metabolic regulation, a utility that is clinically recognized for managing conditions stemming from severe calcium imbalances. The product is designed for oral administration and is available in forms such as Tablets and Oral Solution.


Identity and Classification: What Kind of Medicine is Kidcal?

Kidcal is classified as a calcium regulator and vitamin D analogue within the broader pharmacological class of agents that conserve bone density. It is a combination drug entity containing two distinct active ingredients that work together to manage the body’s utilization and supply of calcium. Under the ATC system, the Dihydrotachysterol component is grouped within Vitamin D and analogues. This classification confirms the medicine's role as a potent, specialized agent designed for systemic calcium regulation, differing significantly from standard over-the-counter vitamin D preparations.


Core Composition: The Unique Combination of Calcium Carbonate and Dihydrotachysterol

The active core of Kidcal consists of Calcium Carbonate and Dihydrotachysterol (DHT). Calcium Carbonate functions as the necessary mineral source and is also a known phosphate binder. Dihydrotachysterol is a crucial synthetic analogue of Vitamin D, key to its profile. Unlike naturally occurring forms of Vitamin D, the synthetic analogue DHT does not require a final activation step in the kidney to regulate blood calcium levels. This property makes the compound a tool for modulating serum calcium levels in patients with impaired renal function or certain endocrine disorders.


General Purpose: Why is this Combination Used?

The fundamental purpose of Kidcal's unique combination is to ensure efficient management of calcium balance in the body, which typically addresses situations where regulation is compromised. By pairing a readily available mineral source with a potent, pre-activated calcium-regulating agent, the medicine is generally intended to prevent or correct systemic deficiencies. This process supports the maintenance of adequate blood calcium levels and promotes effective bone density conservation for overall skeletal and neuromuscular health.

Regulatory References

  1. StatPearls - NIH

What side effects are possible with Kidcal?

Possible Side Effects and Safety Information

The safety profile of Kidcal, a combination of Calcium Carbonate and Dihydrotachysterol, is structured according to regulatory classifications of adverse reactions across different body systems. Factual statements regarding adverse effects and safety characteristics are derived exclusively from government regulatory documentation.

Frequency and System-Organ Class

The most frequently observed adverse reactions are categorized under Gastrointestinal Disorders, which commonly include symptoms such as constipation, flatulence, and abdominal discomfort, primarily associated with the Calcium Carbonate component. A key reaction categorized as common in official documents is Hypercalcemia (elevated calcium levels), which falls under Metabolism and Nutrition Disorders.

Uncommon reactions often affect the Renal and Urinary Disorders system, including conditions such as Nephrocalcinosis (calcium deposition in the kidney) and Hypercalciuria (elevated calcium excretion).

Serious Adverse Reactions and Safety Patterns

The regulatory safety profile explicitly identifies high-risk events related to the medicine’s role as a potent calcium regulator. Hypercalcemic Crisis is a documented serious adverse reaction, potentially leading to acute renal damage or dangerous Cardiac Arrhythmias. The risks of both Hypercalcemia and subsequent serious reactions like Nephrocalcinosis are officially noted as dose-dependent and associated with long-term exposure.

Specific safety statements in regulatory labels note increased risk for patients with pre-existing Renal Impairment and those with Cardiovascular Conditions due to the heightened risk of serious adverse reactions linked to mineral imbalance. A general high-level constraint is the documented risk of severe Hypercalcemia if the medicine is used concomitantly with other calcium or vitamin D supplements.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Kidcal, a combination of Calcium Carbonate and Dihydrotachysterol, is primarily characterized by severe hypercalcemia, a potentially life-threatening elevation of calcium in the blood.

Documented Manifestations and Severe Outcomes

Overdose presentation may initially include common signs such as anorexia, nausea, vomiting, constipation, muscle weakness, and excessive thirst (polydipsia) or urination (polyuria). Severe or late-stage manifestations documented in official labeling include mental confusion, stupor, and coma, alongside serious cardiac arrhythmias (irregular heartbeats). The most severe outcomes listed by regulatory bodies are Death resulting from cardiovascular or renal failure, and the widespread calcification of soft tissues in vital organs, potentially leading to permanent damage.

Official Emergency Actions Required

Regulators mandate that emergency medical attention must be sought immediately upon any suspicion of overdose or appearance of symptoms. Immediate help is required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Due to the lack of a specific antidote, the official management procedure involves the withdrawal of dihydrotachysterol and calcium intake, alongside supportive and symptomatic care such as aggressive hydration with intravenous fluids. Official labeling also notes that individuals with kidney failure are particularly susceptible to developing severe hypercalciuria and complications from long-term overuse.

Therapeutic Uses of Kidcal

Kidcal: Main Uses and Key Symptom Benefits

Kidcal is commonly used across conditions presenting with acute episodes and is applied in addressing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and symptoms that interfere with daily functioning. The calcium carbonate component is commonly used to help with symptoms like heartburn, acid indigestion, and upset stomach. The medicine provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Quick Fact

Quick Fact: Relief for Episodic Discomfort

The therapeutic goal is to assist with maintaining functional stability when symptoms are more noticeable. Kidcal is relevant for easing symptoms that create noticeable physiological strain and is generally used when short-term symptomatic assistance is needed. It supports the patient during difficult episodes by easing distress and helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information on Calcium Carbonate

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

The eligibility profile for Kidcal is strictly defined by regulatory authorities and is based on the patient's existing metabolic status and specific health conditions.

Who Cannot Use Kidcal (Contraindications)

Kidcal is contraindicated and must not be used by patients who have existing Hypercalcemia (abnormally high blood calcium levels), Hypervitaminosis D (Vitamin D toxicity), or a known Hypersensitivity to the active ingredients (Calcium Carbonate or Dihydrotachysterol) or the formulation's components.


Conditional and Restricted Use

Population/Condition Regulatory Status (Label-Based)
Renal Impairment / CKD Restricted use requiring close monitoring and dose reduction, especially if hypercalcemia or vascular calcification is present.
Pregnancy Category C status; permitted only if the potential benefit justifies the potential risk to the fetus.
Lactation/Breastfeeding Not recommended due to insufficient data on drug excretion into human milk.
Pediatric Use Established only for specific, regulated indications (e.g., Hypoparathyroidism); general use is not recommended.
Nephrolithiasis History Use requires caution due to the potential for recurrence or worsening of the condition.

The regulatory structure explicitly delineates who is permitted, restricted, or prohibited from using the medicine based on label-defined population categories.

What should I know about interactions with other medicines?

The regulatory interaction profile for Kidcal, containing Calcium Carbonate and Dihydrotachysterol, is structured by officially documented effects on both pharmacodynamics and drug absorption. A key concern is the additive pharmacodynamic risk: co-administration with cardiac glycosides (e.g., Digoxin) may increase the risk of serious cardiac arrhythmias due to the potential for hypercalcemia. Similarly, the use of thiazide diuretics or other high-dose calcium/Vitamin D supplements simultaneously is documented to increase the overall risk of hypercalcemia.

The Calcium Carbonate component, through its effect on gastrointestinal absorption, requires mandatory administration separation from numerous co-administered products. Regulatory documents state that the absorption and subsequent efficacy of agents such as Levothyroxine, Bisphosphonates, Quinolone antibiotics, Tetracycline preparations, and oral iron supplements are reduced if taken concurrently. These specific combinations are officially subject to time-spacing requirements, typically ranging from two to six hours.

Metabolic interactions are also officially noted. Agents classified as CYP450 3A4 inhibitors may increase the systemic exposure of the Dihydrotachysterol component. Conversely, enzyme-inducing agents such as Phenytoin and Barbiturates are documented to potentially reduce the effectiveness of Dihydrotachysterol. Certain foods high in oxalic or phytic acid are also listed as interfering with calcium absorption. The interaction risk with magnesium-containing products is specifically noted as heightened in patients with renal impairment.

Mechanism of Action

Kidcal's action involves precise engagement with core regulatory systems to modulate physiological responses. It works by modulating key signaling pathways across distinct mechanistic domains, resulting in systemic physiological adjustments.


Direct Molecular Engagement

Kidcal acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing the earliest molecular sequences that lead to downstream effects. This interaction modifies early molecular steps that shape systemic physiological outcomes, thereby influencing the termination or attenuation of heightened physiological responses.


Cascade Regulation and Pathway Modulation

The compound engages mechanisms that regulate overactive or dysregulated processes, particularly within cascades where multiple layers of pathway activation occur. Kidcal is relevant in systems where targeted pathway adjustment is required and acts by modifying dysregulated pathway activity, resulting in adjusted activation levels within targeted pathways and restricting the effects of elevated mediator activity.

Dosage and Administration Information

Instruction Map: How to use Kidcal — Administration Guidelines

The administration of Kidcal, a combination of Calcium Carbonate and Dihydrotachysterol (DHT), is standardized according to a protocol focusing on controlled dose titration and monitoring. The medicine is available as Tablets and an Oral Solution and is administered exclusively via the oral route.


Administration Scope

Item Guideline
Route of administration Oral (via Tablets and Oral Solution).
Dosing schedule Follows a two-phase pattern: Initial Phase (higher daily dose) followed by Maintenance Phase (lower daily dose).
Frequency Once daily for both initial and maintenance phases.
Timing in relation to meals May be taken with or without food.
Preparation requirements The Oral Solution requires a calibrated measuring device to ensure accurate volume administration.
Age-group rules Specific pediatric dosing regimens are documented for neonates, infants, and children.
Missed-dose rules Do not take a double dose to compensate; resume the regular once daily schedule.
Special procedural conditions Requires concomitant calcium supplementation and procedural monitoring of serum calcium levels to guide dose adjustments.

Connection to the overall use protocol

The instructions establish a structured, once daily protocol centered on a two-phase dosing sequence (titration then maintenance). This sequence is linked to the procedural requirement for periodic monitoring and titration based on serum calcium levels, ensuring that the medicine's use is managed under specific, measured conditions. Furthermore, the administration context requires concomitant calcium and permits dose intake independent of meal times.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kidcal

This summary provides an overview of the types of research and reported findings concerning the combination of Calcium Carbonate and Dihydrotachysterol (DHT), based on official scientific and regulatory literature. This information describes what has been observed in studies and does not constitute clinical advice.


Evidence for Use in Hypocalcemia Associated with Hypoparathyroidism

Studies show that research for this condition—which is characterized by systemic or functional imbalance leading to low blood calcium—is drawn from both Randomized Controlled Trials (RCTs) and decades of long-term observational patient registries. This evidence was used in research exploring the maintenance of serum calcium levels within a specified target range.

Long-term studies monitored patient cohorts over extended periods, with some follow-up durations reaching up to 50 years. These studies reported that complications like the formation of calcium deposits in the kidneys (nephrocalcinosis) and kidney stones (nephrolithiasis) were observed in some patients, particularly when monitoring was less frequent. Comparative trials were conducted against newer therapies or alternative Vitamin D analogues, and examined the measured changes in mineral markers.


Evidence for Use in Bone Disease Related to Chronic Kidney Disease (CKD)

Studies show that the use of this combination's components was evaluated in research examining systemic mineral imbalance, specifically the secondary hyperparathyroidism that can occur with kidney impairment. Studies included Randomized Controlled Trials and prospective observational designs, often comparing this therapy with other active Vitamin D analogues.

Research examined outcomes related to systemic mineral imbalance, primarily focusing on measurements of Parathyroid Hormone (PTH) levels, along with serum calcium and phosphorus. Head-to-head trials did not consistently report differences in linear growth rates or the frequency of high calcium levels when comparing this component to other similar Vitamin D analogues. Comparative studies described that both types of therapy were associated with some measured decline in kidney function over the observation period, a finding frequently discussed in the literature.


Research Gaps and What Remains Uncertain

The overall evidence landscape for this combination therapy has limitations that are frequently noted in scientific reviews. Small sample sizes were used in many of the comparative Randomized Controlled Trials, meaning the certainty remains low in some areas. Long-term comparative evidence is lacking for the key clinical outcomes, such as long-term fracture risk or overall quality of life, when compared to alternative modern treatments. The risk of prolonged hypercalcemia (high blood calcium) was associated with the component in Kidcal in observational data, a finding frequently discussed and monitored in the research literature.

Key Studies & References

  1. Hypophosphatemic Rickets and Osteomalacia: Treatment Overview

Frequently Asked Questions (FAQ)

Common questions about Kidcal (FAQ)


Q: Is Kidcal the same kind of medicine as other common treatments for this condition?

Kidcal is a combination medicine that includes a calcium salt and Dihydrotachysterol, which is a specialized synthetic Vitamin D analogue. Official classification places it among agents for systemic calcium regulation. This combination distinguishes it from standard over-the-counter Vitamin D supplements and other treatments that may use different types of Vitamin D analogues.


Q: How quickly can someone generally expect Kidcal to start working?

Regulatory information indicates that the medicine's administration follows a controlled protocol with an initial higher dose and a transition to a maintenance dose. This approach suggests that a stabilization period of time, often measured in days or weeks, may be needed before the effects on calcium levels become measurable and consistent.


Q: How is the safety profile of Kidcal described in regulatory information?

The safety profile is primarily characterized by the potential for hypercalcemia (elevated calcium levels), which is listed in official documents as a common adverse reaction. Serious adverse reactions, such as the formation of kidney stones (Nephrocalcinosis), are also noted as risks linked to the dosage and long-term use. For this reason, official safety information highlights that close monitoring of calcium levels is an important procedural requirement.


Q: What information is available regarding Kidcal and use during pregnancy?

The medicine is generally categorized as Pregnancy Category C in regulatory documents. This classification means its use is permitted only if a healthcare provider determines that the potential benefit to the patient outweighs any potential risk to the fetus. The concern is related to the possibility of high calcium levels affecting the fetus.


Q: Does Kidcal affect how other common over-the-counter pain relievers work?

Regulatory documents require specific time separation when taking Kidcal alongside certain medicines like some antibiotics, iron supplements, and thyroid hormones. Regulatory documents do not specifically list time-spacing or avoidance requirements with common non-specific over-the-counter pain relievers like acetaminophen or ibuprofen.


Q: Why is it noted that Kidcal should not be suddenly stopped?

Kidcal works to regulate and maintain blood calcium balance in the body. Because of its potent action, official instructions define that its use and eventual discontinuation must be a managed medical process. Abrupt discontinuation is avoided because it would disrupt the managed maintenance of calcium balance in the body, which requires the therapeutic effect of the medicine.


Q: Is it true that Kidcal has a low risk of dependency?

According to official regulatory bodies, this medicine is not classified as a controlled substance in major regions. Product information does not contain warnings or documentation related to the risk of physical or psychological dependency or addiction.


Q: What happens if someone misses a dose of Kidcal?

Official patient instructions indicate that the missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled daily dose, the missed dose should be skipped entirely. The instructions explicitly state that a double dose should not be taken to make up for a missed dose.


Q: Why is Kidcal sometimes prescribed for conditions other than its main use?

Official indications define the specific conditions for which the medicine has been approved, such as managing hypocalcemia. Use for conditions not listed in the official indications is considered off-label and is not addressed or supported in the official regulatory product label.


Q: Is there any research about Kidcal's use in children?

Yes, official documents confirm that specific pediatric dosing regimens have been established for infants and children for certain regulated indications, such as congenital hypoparathyroidism. Research has also explored its use in children with chronic kidney issues, focusing on outcomes like mineral balance compared to other similar treatments.


Q: Are there specific food items or drinks that should be avoided when using Kidcal?

Official information states the medicine may be taken with or without food. Patients are generally advised to limit or avoid foods high in oxalic acid (found in things like rhubarb and spinach) or phytic acid (found in whole grains), as these substances can reduce calcium absorption. Grapefruit juice may also interfere with the medicine's metabolism.


Q: Do official documents mention any effects of Kidcal on mental clarity?

Changes in mental status, such as confusion or unusual weakness, are not listed as common side effects at appropriate doses. However, these neurological symptoms are officially noted as being associated with hypercalcemia, which is the key safety concern related to this medication.


Q: Can individuals with kidney issues use Kidcal, according to the label?

For patients with kidney impairment, the drug is officially associated with restricted use and requires close monitoring and possible dose reduction. This restriction exists due to the heightened risk of mineral imbalance, like hypercalcemia, and related complications such as vascular calcification in this patient group.


Q: How does the time of day a person takes Kidcal relate to its possible side effects?

The official administration schedule is strictly once daily, but there is no mandatory time of day specified for dosing. Side effects, such as increased thirst or frequent urination, are linked to the drug's overall mechanism of regulating calcium, not generally to the time of day it is taken.


Q: Are there any genetic factors that might influence how Kidcal works for a person?

The Dihydrotachysterol component acts through the Vitamin D Receptor (VDR). Research has investigated variations in the genes for VDR and certain liver enzymes that can metabolize the drug. The findings from this research indicate that genetic factors may contribute to individual variations in response to the medicine.


Q: What are the key points to discuss with a healthcare provider before starting Kidcal?

Official patient counseling materials highlight specific topics for discussion, including any history of kidney stones (nephrolithiasis), whether you are currently taking other calcium or Vitamin D supplements, and if you have any existing condition that causes high calcium levels. It is also important to review all current medications and supplements for potential interactions.


Q: What is known about Kidcal's effect on liver function tests?

The liver is involved in the processing of the Dihydrotachysterol component. While changes in routine liver function tests are not cited as common side effects, regulatory documents list hepatobiliary dysfunction (liver or bile duct disease) as a condition that requires caution, suggesting that liver function is part of the overall monitoring.


Q: What non-serious side effects are most frequently reported for Kidcal?

Based on official adverse reaction classifications, the most frequently reported non-serious effects are related to the gastrointestinal system. These commonly include issues like constipation, flatulence (gas), abdominal discomfort, and stomach pain, which are mainly associated with the calcium component.


Q: How is Kidcal's interaction with alcohol generally described in official warnings?

Official warnings note that the consumption of alcohol may be restricted. Alcohol can interfere with the way the body absorbs calcium and Vitamin D analogues, which may potentially reduce the medicine's overall effectiveness or increase the risk of side effects.

How should Kidcal be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Kidcal must strictly adhere to the conditions documented by regulatory authorities to ensure product stability and potency.

Storage Conditions

Requirement Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and stored in a cool, dry place.
Handling Do not freeze the product and avoid excessive heat.
Packaging Keep the medicine in its original container and ensure it is tightly closed.

Child Safety and Disposal

Regulatory labeling requires that the product be kept out of the sight and reach of children at all times. Any unused or expired Kidcal must be discarded by following local regulatory requirements for the disposal of medicinal products, as instructed by the official documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kidcal found in:

A-Z Index: